Otsuka Shanghai Research Institute (OSRI) was established in 2008 as a research-based enterprise wholly owned by Otsuka Pharmaceutical Co., Ltd. of Japan, one of the world's leading comprehensive broad-based pharmaceutical companies, with a history of more than 80 years Since its foundation, the primary focus of Otsuka Pharmaceutical’s research has been on the discovery and development of such products as new therapeutic drugs, healthcare products, health foods, medical and diagnostic devices and reagents, and Otsuka has produced and marketed these products along with the relevant services.
         Thanks to the insightful cooperation between China’s State Food and Drug Administration (SFDA) and Otsuka Pharmaceutical, at the time under the leadership of Masahito Otsuka and Akihiko Otsuka, China Otsuka Pharmaceutical Co., Ltd. was successfully established in Tianjin in 1981 as the first joint venture between China and a Japanese company.

         Since its establishment, China Otsuka Pharmaceutical has actively contributed to the reform and opening of China’s medical and pharmaceutical industries.Otsuka has invested heavily in China, while at the same time introducing to China some modern business models and the current good manufacturing practices (GMP) for medical products. As a result, Otsuka has earned a respected reputation and wide recognition throughout China’s medical and pharmaceutical fields.
       OSRI’s activities are expected to further expand Otsuka’s presence in China’s medical and pharmaceutical fields, reflecting the company’s motto of “Otsuka – people creating new products for better health worldwide.”

Copyright©2009-2011 大冢(上海)药物研究开发有限公司版权所有
All Rights Reserved by Otsuka Shanghai Research Institute